CLEC7A and neoplasm: This combination therapy reversed the tumor immunosuppression of M2-like TAMs (M2-TAMs) by disrupting the galectin-9/dectin1 axis and recruited cytotoxic T cells and downregulated Treg cells to stimulate anti-tumor immunity with significant efficacy in cancer therapy [612].